



FINAL REPORT

Bill No.	MGMWPR240100192	Bill Date	06-11-2024 18:39
Patient Name	MR. KIRAN BHAGWAN Taware	UHID	MGM240017131
Age / Gender	56 Yrs 3 Mth / MALE	Patient Type	IPD
Ref. Consultant	DR.PRASHANT ATHALE	Ward	SURGICAL WARD UNIT
Sample ID	MG24165903	Current Bed	SW-518
IP Number	MGMP2406720	Reporting Date & Time	08-11-2024 13:07
		Receiving Date & Time	06/11/2024 19:16

Microbiology Report

MISCELLANEOUS - C/S

Specimen : Tissue
Site : Right abdominal wall
Stains
Gram Stain : Pus cells : Few
: Bacteria :
: Scanty GPC seen.
: Few GNB seen.
Growth Grade : Moderate growth
Organism : **Escherichia coli**

ANTIBIOTICS	INTERPRETATION	MIC
Amikacin	SENSITIVE	Disc diffusion
Amoxicillin/Clavulanic acid	RESISTANT	Disc diffusion
Cefotaxime	RESISTANT	Disc diffusion
Ceftriaxone	RESISTANT	Disc diffusion
Cefuroxime	RESISTANT	Disc diffusion
Cefoperazone	RESISTANT	Disc diffusion
Ceftazidime	RESISTANT	Disc diffusion
Gentamicin	SENSITIVE	Disc diffusion
Netilmicin	SENSITIVE	Disc diffusion
Ciprofloxacin	RESISTANT	Disc diffusion
Ofloxacin	RESISTANT	Disc diffusion
Levofloxacin	RESISTANT	Disc diffusion
Trimethoprim/Sulphamethoxazole	SENSITIVE	Disc diffusion
Piperacillin/Tazobactam	RESISTANT	Disc diffusion
Cefepime	INTERMEDIATE	Disc diffusion
Imipenem	SENSITIVE	Disc diffusion
Meropenem	SENSITIVE	Disc diffusion
Cefaperazone/Sulbactam	RESISTANT	Disc diffusion
Ticarcillin/Clavulanic acid	RESISTANT	Disc diffusion

Method :- Culture on routine culture medium, Quaternary streaking /Semi-quantitative method. Identification done by Biochemical reactions / Automated Vitek-2 . Antimicrobial sensitivity by automated Vitek -2 / conventional methods/estrips.

Note :-

- Result of culture and antimicrobial susceptibility test need to be correlated clinically.
- Previous history of antibiotic usage may influence the growth of microorganisms in vitro.
- Antibiotic susceptibility done as per revised CLSI Guidelines.

Clinical Reference :

- CLSI: Performance standards for Antimicrobial Susceptibility Testing.